An antiapoptotic polymeric nanomedicine, PGA-peptoid 1, has been developed by the conjugation of a novel apoptotic protease activating factor 1 (Apaf-1) inhibitor (peptoid 1) to poly-L-glutamic acid (PGA). Full structural and biophysical characterization of the conjugate by different techniques has been accomplished. This macromolecule clearly enhances the antiapoptotic activity of peptoid 1 in different cell models.
No takes yet. Share an insight, caveat, or question.
Vicent et al. (2006) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: